C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.
BACKGROUND: c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis. METHODS: We identified 15 studies assessing su...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3817069?pdf=render |
| _version_ | 1811273680721805312 |
|---|---|
| author | Shan Yu Yiyi Yu Naiqing Zhao Jianlan Cui Wei Li Tianshu Liu |
| author_facet | Shan Yu Yiyi Yu Naiqing Zhao Jianlan Cui Wei Li Tianshu Liu |
| author_sort | Shan Yu |
| collection | DOAJ |
| description | BACKGROUND: c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis. METHODS: We identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity. RESULTS: 15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622-2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage. CONCLUSIONS: Patients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis. |
| first_indexed | 2024-04-12T23:03:38Z |
| format | Article |
| id | doaj.art-91c496c641eb400b90999597c6ecf006 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T23:03:38Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-91c496c641eb400b90999597c6ecf0062022-12-22T03:12:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e7913710.1371/journal.pone.0079137C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.Shan YuYiyi YuNaiqing ZhaoJianlan CuiWei LiTianshu LiuBACKGROUND: c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis. METHODS: We identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity. RESULTS: 15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622-2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage. CONCLUSIONS: Patients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis.http://europepmc.org/articles/PMC3817069?pdf=render |
| spellingShingle | Shan Yu Yiyi Yu Naiqing Zhao Jianlan Cui Wei Li Tianshu Liu C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS ONE |
| title | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. |
| title_full | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. |
| title_fullStr | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. |
| title_full_unstemmed | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. |
| title_short | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. |
| title_sort | c met as a prognostic marker in gastric cancer a systematic review and meta analysis |
| url | http://europepmc.org/articles/PMC3817069?pdf=render |
| work_keys_str_mv | AT shanyu cmetasaprognosticmarkeringastriccancerasystematicreviewandmetaanalysis AT yiyiyu cmetasaprognosticmarkeringastriccancerasystematicreviewandmetaanalysis AT naiqingzhao cmetasaprognosticmarkeringastriccancerasystematicreviewandmetaanalysis AT jianlancui cmetasaprognosticmarkeringastriccancerasystematicreviewandmetaanalysis AT weili cmetasaprognosticmarkeringastriccancerasystematicreviewandmetaanalysis AT tianshuliu cmetasaprognosticmarkeringastriccancerasystematicreviewandmetaanalysis |